Americana Partners LLC Acquires 54,220 Shares of Pfizer Inc. $PFE

Americana Partners LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 6.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 942,561 shares of the biopharmaceutical company’s stock after purchasing an additional 54,220 shares during the period. Americana Partners LLC’s holdings in Pfizer were worth $24,016,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC grew its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. CX Institutional raised its position in shares of Pfizer by 50.6% during the second quarter. CX Institutional now owns 47,032 shares of the biopharmaceutical company’s stock worth $1,140,000 after acquiring an additional 15,797 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Pfizer by 58.9% during the second quarter. Farther Finance Advisors LLC now owns 135,499 shares of the biopharmaceutical company’s stock valued at $3,284,000 after acquiring an additional 50,209 shares during the period. Finally, Park Avenue Securities LLC bought a new stake in Pfizer during the 2nd quarter worth about $3,807,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Bank of America reduced their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. HSBC reiterated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $27.88.

Pfizer Stock Performance

NYSE:PFE opened at $25.68 on Tuesday. The stock has a market cap of $146.01 billion, a P/E ratio of 14.93 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $25.38 and its two-hundred day moving average price is $24.99. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.